Piper Sandler initiated coverage on Pelthos Therapeutics Inc. with a new price target
Stocks in this Quantisnow insightHealth Care
Historical context for PTHS
Across the 9 sessions after earlier PTHS headlines, the stock closed higher 4 times and lower 5 times, with a median move of 5.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | PTHS | SPY |
|---|---|---|---|
| Feb 23, 2026 | Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | +5.0% | -1.0% |
| Jan 5, 2026 | Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice | -9.0% | +0.7% |
| Dec 24, 2025 | Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn | -1.8% | +0.4% |
| Dec 4, 2025 | Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3% | +0.6% | +0.1% |
| Dec 3, 2025 | Lake Street initiated coverage on Pelthos Therapeutics Inc. with a new price targetand 1 other headline that session | +4.2% | +0.3% |
| Dec 2, 2025 | Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference | -5.0% | +0.2% |
Quantisnow market dataAMEX
PTHS
Pelthos Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2024
Get push alerts for PTHS
Full PTHS profile on Quantisnow Follow PTHS and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time